Efficacy of teriparatide compared with risedronate on FRAX^®-defined major osteoporotic fractures: results of the VERO clinical trial.

ABSTRACT: FRAX^® calculates the 10-year probability of major osteoporotic fractures (MOF), which are considered to have a greater clinical impact than other fractures. Our results suggest that, in postmenopausal women with severe osteoporosis, those treated with teriparatide had a 60% lower risk of FRAX^®-defined MOF compared with those treated with risedronate.

Introduction

The VERO trial was an active-controlled fracture endpoint clinical trial that enrolled postmenopausal women with severe osteoporosis. After 24 months, a 52% reduction in the hazard ratio (HR) of clinical fractures was reported in patients randomized to teriparatide compared with risedronate. We examined fracture results restricted to FRAX^®-defined major osteoporotic fractures (MOF), which in

SUBMITTER: Body JJ 

PROVIDER: S-EPMC7497508 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature